• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Study to assess merger of Epi-LASIK, wavefront

Article

Duluth, GA-Norwood Abbey Ltd. has launched a 3-month study of postoperative comfort, visual recovery, and wavefront-guided custom ablation with its Centurion SES Epikeratome with EpiEdge for Epi-LASIK for the treatment of myopia.

Duluth, GA-Norwood Abbey Ltd. has launched a 3-month study of postoperative comfort, visual recovery, and wavefront-guided custom ablation with its Centurion SES Epikeratome with EpiEdge for Epi-LASIK for the treatment of myopia.

Marguerite B. McDonald, MD, FACS, will serve as principal investigator and medical monitor; Daniel S. Durrie, MD, and Lee Shahinian, MD, are clinical investigators.

The study will examine how combining Epi-LASIK and wavefront diagnostics would affect visual outcomes. Some 35 patients will be enrolled at each of three U.S. study sites.

Related Videos
Katherine Talcott, MD, presenting slides
Katherine Talcott, MD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.